PE20070325A1 - Formas de dosificacion oral que comprenden compuestos derivados de carbamato - Google Patents
Formas de dosificacion oral que comprenden compuestos derivados de carbamatoInfo
- Publication number
- PE20070325A1 PE20070325A1 PE2006000742A PE2006000742A PE20070325A1 PE 20070325 A1 PE20070325 A1 PE 20070325A1 PE 2006000742 A PE2006000742 A PE 2006000742A PE 2006000742 A PE2006000742 A PE 2006000742A PE 20070325 A1 PE20070325 A1 PE 20070325A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- oral dosage
- compounds
- compound
- dosage forms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 239000006186 oral dosage form Substances 0.000 title abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical compound C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000007101 Muscle Cramp Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE UN COMPUESTO DE FORMULA (I) O UN COMPUESTO DE FORMULA (II), DONDE X ES UN HALOGENO; R1, R2, R3, R4, R5 Y R6 SON H O ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO CON FENILO QUE ESTA OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C4), ALCOXI(C1-C4), NH, NITRO O CN; DICHOS COMPUESTOS COMPRENDEN ENANTIOMEROS DE FORMULA (Ia), (IIa), ENTRE OTROS, O MEZCLAS RACEMICAS DE LOS MISMOS, EN DONDE PREDOMINA UN ENANTIOMERO EN UNA CANTIDAD DE 90%. SE REFIERE TAMBIEN A UNA ESTRUCTURA DE DOSIFICACION ORAL DE LIBERACION SOSTENIDA QUE LIBERA DE MODO SOSTENIDO EL COMPUESTO DE FORMULA (I) O (II) A VELOCIDADES QUE PROVEEN UNA CONCENTRACION PLASMATICA MAXIMA PROMEDIO DE DOSIS UNICA Cmax DEL COMPUESTO DE FORMULA (I) O (II), QUE SATISFACEN LA RELACION 5ng/ml/mg £ Cmax £ 16ng/ml/mg; Y DISPOSITIVOS QUE PERMITAN UNA DOSIFICACION DE DICHOS COMPUESTOS DE MODO QUE REDUZCA SUS EFECTOS SECUNDARIOS. LA CANTIDAD LIBERADA DE LOS COMPUESTOS DE LA FORMA DE DOSIFICACION ORAL A LAS 2 HORAS ES DE 10% EN PESO DE LA DOSIS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CONVULSIONES, EPILEPSIA, ATAQUE APOPLEJICO, ESPASMO MUSCULAR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69571505P | 2005-06-29 | 2005-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070325A1 true PE20070325A1 (es) | 2007-05-12 |
Family
ID=37310173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000742A PE20070325A1 (es) | 2005-06-29 | 2006-06-27 | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070004797A1 (es) |
| EP (1) | EP1898885A1 (es) |
| AR (1) | AR054524A1 (es) |
| CA (1) | CA2613933A1 (es) |
| PE (1) | PE20070325A1 (es) |
| TW (1) | TW200740429A (es) |
| WO (1) | WO2007002906A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| JP5161075B2 (ja) * | 2005-06-03 | 2013-03-13 | エガレット エイ／エス | 分散媒体の第１フラクションとマトリックスの第２フラクションを有し、第２フラクションが胃腸の液体に少なくとも部分的に最初に曝される固形の医薬組成物 |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
| AU2008207200B2 (en) * | 2007-01-16 | 2011-02-17 | Egalet Ltd | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
| US20080292692A1 (en) * | 2007-05-21 | 2008-11-27 | Shira Pilch | Impermeable Capsules |
| WO2008148798A2 (en) * | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| CA2696341C (en) | 2007-08-13 | 2016-05-17 | Abuse Deterrent Pharmaceutical Llc | Abuse resistant drugs, method of use and method of making |
| CA2750400A1 (en) * | 2009-01-26 | 2010-07-29 | Egalet A/S | Controlled release formulations with continuous efficacy |
| US8603526B2 (en) * | 2009-02-06 | 2013-12-10 | Egalet Ltd. | Pharmaceutical compositions resistant to abuse |
| AU2010211220B2 (en) | 2009-02-06 | 2013-08-01 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| WO2010149169A2 (en) | 2009-06-24 | 2010-12-29 | Egalet A/S | Controlled release formulations |
| EP2720686A4 (en) * | 2011-06-15 | 2014-12-17 | Orient Pharma Co Ltd | MULTILAYER CAPSULE AND MANUFACTURING METHOD THEREFOR |
| US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| WO2014146093A2 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| MXPA03007719A (es) * | 2001-02-27 | 2004-11-12 | Johnson & Johnson | Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos neurodegenerativos. |
| ES2342185T3 (es) * | 2004-09-16 | 2010-07-02 | Janssen Pharmaceutica Nv | Uso de (di)carbamatos de 2-fenil-1,2-etanodiol para el tratamiento de la epileptogenesis. |
-
2006
- 2006-06-27 PE PE2006000742A patent/PE20070325A1/es not_active Application Discontinuation
- 2006-06-28 TW TW095123239A patent/TW200740429A/zh unknown
- 2006-06-28 AR ARP060102781A patent/AR054524A1/es not_active Application Discontinuation
- 2006-06-29 WO PCT/US2006/025692 patent/WO2007002906A1/en not_active Ceased
- 2006-06-29 CA CA002613933A patent/CA2613933A1/en not_active Abandoned
- 2006-06-29 EP EP06786031A patent/EP1898885A1/en not_active Withdrawn
- 2006-06-29 US US11/478,241 patent/US20070004797A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20070004797A1 (en) | 2007-01-04 |
| WO2007002906A1 (en) | 2007-01-04 |
| CA2613933A1 (en) | 2007-01-04 |
| TW200740429A (en) | 2007-11-01 |
| AR054524A1 (es) | 2007-06-27 |
| EP1898885A1 (en) | 2008-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070325A1 (es) | Formas de dosificacion oral que comprenden compuestos derivados de carbamato | |
| PE20060285A1 (es) | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) | |
| PE20040832A1 (es) | Derivados de indolil pirazinona | |
| PE20110215A1 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
| PE20060842A1 (es) | Amino-imidazolonas para la inhibicion de b-secretasa | |
| AR050958A1 (es) | Antibioticos biciclicos | |
| PE20070720A1 (es) | Derivados de fenilo como antagonistas del receptor 3 de la histamina | |
| AR061066A1 (es) | Coterapeutica para el tratamiento de epilepsia y trastornos relacionados | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| TW200508180A (en) | Therapeutic agents | |
| SV2003000162A (es) | Los inhibidores triciclicos de poli (adp-ribosa) polimerasas | |
| ES2173846T3 (es) | Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2. | |
| CR9053A (es) | Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia | |
| AR033426A1 (es) | Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento | |
| PE20080929A1 (es) | Metodos para el tratamiento de la depresion | |
| AR035756A1 (es) | Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos | |
| PE20120217A1 (es) | Derivados de carbamatos de alquil-heterociclos, su preparacion y su aplicacion en terapeutica | |
| MY133370A (en) | Carbamate compounds for use in preventing or treating bipolar disorders | |
| AR033427A1 (es) | Uso de compuestos carbamatos en el tratamiento del dolor | |
| RU2003128997A (ru) | Карбаматы для применения для предотвращения или лечения биполярного расстройства | |
| ECSP088602A (es) | Compuestos con efectos medicinales debido a la interacción con el receptor de glucocorticoides | |
| PE20060630A1 (es) | Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie | |
| MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
| UY27560A1 (es) | Compuestos hexaciclicos- | |
| PE20061113A1 (es) | Compuestos heterociclos como agonistas de ligandos selectivos de erb |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |